Publications by authors named "D T Patton"
User adherence contributes to the effectiveness of topical pre-exposure prophylactic products designed to protect against human immunodeficiency virus type 1 (HIV-1) infection. Long-acting approaches that do not require daily or coitally-dependent use could potentially improve user adherence. This study aims to develop a long-acting vaginal film to deliver an integrase inhibitor, MK-2048, for prevention of HIV-1 infection.
View Article and Find Full Text PDFPurpose: The NCI-MATCH trial assigned patients with solid tumors, lymphomas, or multiple myeloma to targeted therapies on the basis of identified genetic alterations from tumor biopsies. In preclinical models, ()-inactivated tumors display sensitivity to focal adhesion kinase (FAK) inhibition. The EAY131-U subprotocol evaluated the efficacy of defactinib, a FAK inhibitor, in patients with -altered tumors.
View Article and Find Full Text PDFPurpose: Mismatch repair deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy treatment.
Experimental Design: We undertook integrated evaluation performed on samples collected from 28 of 42 patients enrolled on the NCI-MATCH arm Z1D trial that evaluated PD-1 inhibition treatment with nivolumab in patients with non-colorectal dMMR tumors.
Purpose: The NCI-MATCH study is a tumor-agnostic platform trial enrolling patients to targeted therapies on the basis of genomic alterations. Subprotocol V investigated sunitinib in patients with tumors harboring - mutations.
Methods: EAY131-V, is an open-label, single-arm, phase II study.
Dressings and topical agents for preventing pressure ulcers.
Cochrane Database Syst Rev
December 2024
Article Synopsis
- Pressure ulcers are serious injuries caused by prolonged pressure on the skin, especially over bony areas, and they pose significant challenges in healing and treatment costs.
- This review evaluates the effectiveness of various dressings and topical agents in preventing pressure ulcers for individuals at risk, without any existing ulcers, across different healthcare settings.
- The update includes 51 trials with over 13,000 participants, showing that certain dressings, like silicone foam, can significantly reduce the incidence of pressure ulcers compared to no dressing at all.